Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells

Cancer Investigation

Volumn 30, Issue 9, 2012, Pages 657-662

  Wang, Xiaofang ^a   Zhang, Zhiqing ^b   Yao, Cheng ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN FOURTH CENTRAL HOSPITAL   (China)

^c JILIN UNIVERSITY   (China)

Author keywords

Angiogenesis; Bortezomib; MSCs; Multiple Myeloma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BORTEZOMIB; SCATTER FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; BORONIC ACIDS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLAST GROWTH FACTOR 2; HEPATOCYTE GROWTH FACTOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MESENCHYMAL STROMAL CELLS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PYRAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867725029     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.725442     Document Type: Article

References (14)

1. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006;20:193-199.
2. Drexler HC, Risau W, Kondering MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;14:65-77.
3. Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omura S, Tanaka K. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998;246:243-248.
4. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vitro and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
5. RoccaroAM,Hideshima T, RajeN, Kumar S, IshitsukaK, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. Bortezomibmediates antiangiogenesis inmultiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-191.
6. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-435.
7. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A,Dammacco F, Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-4155.
8. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006;25:4257-4266.
9. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Rev Cancer 2007;7:585-598.
10. Dvorak, HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl JMed 1986;315:1650-1659.
11. Roche S, Delorme B, Oostendorp RA, Barbet R, Caton D, Noel D, Boumediene K, Papadaki HA, Cousin B, Crozet C, Milhavet O, Casteilla L, Hatzfeld J, Jorgensen C, Charbord P, Lehmann S. Comparative proteomic analysis of humanmesenchymal and embryonic stem cells: towards the definition of a mesenchymal stem cell proteomic signature. Proteomics 2009;9:223-232.
12. Wang X, Zhang Z, Yao C. Angiogenic activity of Mesenchymal Stem Cells in multiple myeloma. Cancer Invest 2011;29:37-41.
13. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol 2003;120:10-17.
14. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607-612.